Keratitis Sicca Clinical Presentation

  • Author: Mark Ventocilla, OD, FAAO; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Jan 4, 2012
 

History

Depending on the severity of keratitis sicca, the following are the most common patient complaints:

  • Foreign body sensation and ocular dryness and grittiness, typically worse toward the end of the day
  • Hyperemia
  • Mucoid discharge
  • Ocular irritation (exacerbated by smoky or dry environments, indoor heating systems, prolonged reading, or computer use)
  • Excessive tearing (secondary to reflex secretion)
  • Fluctuating and/or blurry vision

Documenting the history of exacerbating or alleviating factors and a systemic past medical history is important, including a history of connective tissue disease, thyroid disease, and rheumatoid arthritis.

A review of systems focused on rheumatologic disease; history of neoplasias; and gastrointestinal and ear, nose, and throat (ENT) symptoms should be documented. In addition, ask about a history of dry mouth and request a list of systemic and topical medications the patient is using.

Next

Physical Examination

Before placing any drops in the eye of a patient suspected with keratitis sicca, perform an external and slit lamp examination.

A slit-lamp examination may document some of the following important findings:

  • Decreased tear meniscus
  • Increased debris in the tear film
  • Conjunctival pleating
  • Superficial punctate keratopathy (with positive fluorescein, lissamine green and/or rose bengal staining)
  • Conjunctival hyperemia
  • Mucous plaques and discharge
  • Xerostomia (dry mouth) (in association with Sjögren syndrome)
  • Corneal filaments
  • Corneal epithelial defects or ulceration in more severe cases

Determine tear breakup time after placing a drop of fluorescein in the cul-de-sac.

Use rose Bengal staining to look for conjunctival and corneal staining, particularly at the nasal and temporal limbus and/or inferior paracentral cornea.

Perform the 5-minute Schirmer test with and without anesthesia using a Whatman #41 filter paper that is 5 mm in width × 35 mm in length. (Wetting < 5 mm with anesthesia and < 10 mm without anesthesia are considered abnormal.)

Measure reflex secretion with a Schirmer II test if the initial Schirmer test is abnormal. The Schirmer II test is performed by irritating the nasal mucosa with a cotton-tipped applicator before measuring tear production with a Whatman #41 filter paper. (Wetting < 15 mm after 5 min is considered abnormal.)

Previous
Next

Sjögren Syndrome

Sjögren syndrome is characterized by the combination of aqueous tear deficiency and dry mouth (xerostomia). Women comprise 90-95% of patients with this syndrome that has been classified into 3 different subsets, as follows:

  • Patients with systemic immune dysfunction but no defined connective tissue disease (primary Sjögren syndrome)
  • Patients who lack evidence of systemic immune dysfunction or a defined connective tissue disease
  • Patients who have a defined connective tissue disease, most commonly rheumatoid arthritis (secondary Sjögren syndrome). Dry eye is common in patients with rheumatoid arthritis, including those without Sjögren syndrome.[3] Dry eye should always be taken into consideration regardless of the rheumatoid arthritis activity, because the severity of dry eye is independent of the rheumatoid arthritis activity.

All cases of Sjögren syndrome are characterized by a progressive lymphocytic (predominantly B and CD4 lymphocytes) infiltration of the lacrimal and salivary glands that leads to disorganization of the normal gland architecture and consequent loss of function. At this time, the most comprehensive criteria for a diagnosis of Sjögren syndrome include the following:

  • Abnormally low Schirmer test
  • Objective evidence of low salivary flow
  • Biopsy-proven lymphocytic infiltration of the labial salivary glands
  • Dysfunction of the immune system as manifested by the presence of serum autoantibodies (eg, antinuclear antibodies, rheumatoid factor, anti-Ro [SS-A] and anti-La [SS-B] antibodies)

The following are autoimmune disorders associated with Sjögren syndrome:

  • Rheumatoid arthritis
  • Scleroderma
  • Polymyositis
  • Polyarteritis nodosa
  • Hashimoto thyroiditis
  • Chronic hepatobiliary cirrhosis
  • Lymphocytic interstitial pneumonitis
  • Thrombocytopenic purpura
  • Hypergammaglobulinemia
  • Waldenström macroglobulinemia
  • Progressive systemic sclerosis
  • Dermatomyositis
  • Interstitial nephritis
Previous
 
 
Contributor Information and Disclosures
Author

Mark Ventocilla, OD, FAAO  Clinical Professor, Michigan College of Optometry; Editor, American Optometric Association Ocular Surface Society Newsletter; Chief Executive Officer, Elder Eye Care Group, PLC; President, Lakeshore Professional Eyecare, PC

Mark Ventocilla, OD, FAAO is a member of the following medical societies: American Academy of Optometry and American Optometric Association

Disclosure: Nothing to disclose.

Coauthor(s)

Marc R Bloomenstein, OD, FAAO  Director of Optometric Services, Schwartz Laser Eye Center; Adjunct Assistant Professor, Arizona College of Optometry; Adjunct Assistant Professor, Southern California College of Optometry

Marc R Bloomenstein, OD, FAAO is a member of the following medical societies: American Academy of Optometry, American Optometric Association, Arizona Optometric Association, and International Society of Cataract and Refractive Surgeons

Disclosure: Nothing to disclose.

Jacqueline Freudenthal, MD  Co-Investigator, Ophthalmic Consultants Centre, Toronto

Jacqueline Freudenthal, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, and Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Fernando H Murillo-Lopez, MD  Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Simon K Law, MD, PharmD Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

References
  1. Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. Feb 2006;113(2):198-205. [Medline].

  2. Foulks GN. The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol. Jul-Aug 2007;52(4):369-74. [Medline].

  3. Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. Nov 2005;140(5):808-13. [Medline].

  4. Geerling G, Tost FH. Surgical occlusion of the lacrimal drainage system. Dev Ophthalmol. 2008;41:213-29. [Medline].

  5. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. Oct 2005;112(10):1790-4. [Medline].

  6. Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. Jul 2005;21(7):1057-63. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.